GlassScriptPhysician profile
Rene A Reyes
NPI 1083634372
$2,342.70
in general payments reported to CMS, 2019-2025
25 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $224 · 2021: $415 · 2022: $338 · 2023: $490 · 2024: $179 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $532.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $411.95 | 2019-2025 | |
| Pfizer INC. | $256.44 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.87 | 2025 | Lifevest |
| Medtronic, INC. | $148.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $79.30 | 2020 | |
| Intuitive Surgical, INC. | $66.55 | 2023 | Da Vinci Surgical System |
| Abbott Laboratories | $58.71 | 2019-2025 | Freestyle Libre, Proclaim |
| Inspire Medical Systems, INC. | $58.24 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $58.05 | 2023 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $47.02 | 2020-2022 | |
| Amgen INC. | $45.11 | 2019-2023 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $41.25 | 2024 | Voquezna |
| Coloplast Corp | $40.03 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31.97 | 2025 | |
| Horizon Therapeutics Plc | $28.16 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $27.25 | 2019 | |
| Corcept Therapeutics | $24.81 | 2025 | Korlym |
| Viiv Healthcare Company | $21.71 | 2023 | Apretude |
| Phadia US INC. | $17.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.09 | 2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $16.05 | 2019 | |
| Tolmar, INC. | $15.57 | 2023 | |
| Shield Therapeutics INC | $13.54 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.